<DOC>
	<DOCNO>NCT02343445</DOCNO>
	<brief_summary>The goal study evaluate safety tolerability P-1037 determine whether combination P-1037 hypertonic saline P-1037 alone great effect lung function patient CF placebo ( 0.17 % saline ) .</brief_summary>
	<brief_title>Clearing Lungs With ENAC Inhibition Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Male female , 12 year age old . Diagnosis cystic fibrosis determine 1997 CF Consensus criterion ( NIH Consensus Statement , 1997 ) Nonsmoker FEV1 Screening Visit 1 40 % 90 % Stable regimen CF medication chest physiotherapy 28 day prior Screening . Must willing discontinue use hypertonic saline duration study . Clinically stable least 2 week All female childbearing potential must negative serum pregnancy test sexually active must agree practice highly effective form contraception throughout study 28 day last dose study medication . History organ transplantation significant disease disorder Use diuretic ( include amiloride ) reninangiotensin antihypertensive drug trimethoprim 28 day prior Screening History significant intolerance inhale hypertonic saline , determine Investigator Known hypersensitivity study drug amiloride Any clinically significant laboratory abnormality Screening Visit 1 judge investigator , follow : Potassium ≥ 5 mEq/L Abnormal renal function Abnormal liver function , define ≥ 3 x upper limit normal ( ULN ) Hemoglobin level &lt; 10.0 g/dL Female pregnant lactate History sputum throat swab culture yield Burkholderia specie Mycobacterium abscessus within 2 year screen Has previously participate investigational trial involve administration investigational compound use investigational device 28 day prior Screening Currently treat ivacaftor contain regimen</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>